European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

AstraZeneca1,280 enrolled

Overview

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Study Type

OBSERVATIONAL

Enrollment

1,280

Conditions

Acute Bipolar Manic Episode

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with Bipolar Disorder (ICD-10). * Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010 * Patients treated with quetiapine IR or quetiapine XR during the hospitalization period. Exclusion Criteria: * Patients in which BD is not the main reason for hospitalization * Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes * Patients receiving both quetiapine IR and XR during the same hospitalization period.

Locations (86)

Outcomes

Primary Outcomes

Length of hospital stay

Secondary Outcomes

Use of resources

Treatments used

Demographics

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Assebroek, Belgium, Belgium

Research Site

Bertrix, Belgium, Belgium

Research Site

Bruges, Belgium, Belgium

Research Site

Ghent, Belgium, Belgium

Research Site

Godinne, Belgium, Belgium

Research Site

Ixelles-Elsene, Belgium, Belgium

Research Site

Koksijde, Belgium, Belgium

Research Site

Malle, Belgium, Belgium

Research Site

Marchienne-au-Pont, Belgium, Belgium

Research Site

Montignies-sur-Sambre, Belgium, Belgium

...and 76 more locations